Rhumbline Advisers Atea Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 129,796 shares of AVIR stock, worth $379,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares

129,796

Previous 133,114 2.49%

Holding current value

$379,004

Previous $445,000 2.47%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	SELL	$2.93 - $3.82 $9,721 - $12,674	-3,318 Reduced 2.49%	129,796 $434,000
Q3 2024 Nov 12, 2024	SELL	$3.17 - $4.02 $14,214 - $18,025	-4,484 Reduced 3.26%	133,114 $445,000
Q2 2024 Aug 01, 2024	SELL	$3.31 - $4.04 $14,246 - $17,388	-4,304 Reduced 3.03%	137,598 $455,000
Q1 2024 May 09, 2024	SELL	$3.09 - $4.56 $16,111 - $23,775	-5,214 Reduced 3.54%	141,902 $573,000
Q4 2023 Feb 08, 2024	BUY	$2.8 - $3.35 $35,862 - $42,906	12,808 Added 9.54%	147,116 $448,000
Q3 2023 Nov 09, 2023	SELL	$3.0 - $3.79 $20,241 - $25,571	-6,747 Reduced 4.78%	134,308 $402,000
Q2 2023 Aug 08, 2023	BUY	$3.21 - $5.06 $55,751 - $87,882	17,368 Added 14.04%	141,055 $527,000
Q1 2023 May 11, 2023	BUY	$3.0 - $4.97 $16,782 - $27,802	5,594 Added 4.74%	123,687 $414,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $8,608 - $12,210	1,979 Added 1.7%	118,093 $568,000
Q3 2022 Nov 10, 2022	BUY	$5.49 - $8.79 $35,146 - $56,273	6,402 Added 5.84%	116,114 $661,000
Q2 2022 Aug 11, 2022	BUY	$5.33 - $8.18 $146,441 - $224,745	27,475 Added 33.41%	109,712 $779,000
Q1 2022 May 12, 2022	SELL	$5.5 - $9.19 $22,011 - $36,778	-4,002 Reduced 4.64%	82,237 $594,000
Q4 2021 Feb 10, 2022	BUY	$7.67 - $44.59 $4,195 - $24,390	547 Added 0.64%	86,239 $771,000
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $76,702 - $126,075	3,596 Added 4.38%	85,692 $3 Million
Q2 2021 Aug 05, 2021	BUY	$19.22 - $59.08 $1.25 Million - $3.84 Million	64,933 Added 378.33%	82,096 $1.76 Million
Q1 2021 May 06, 2021	BUY	$41.42 - $88.44 $192,478 - $410,980	4,647 Added 37.13%	17,163 $1.06 Million
Q4 2020 Feb 10, 2021	BUY	$26.36 - $41.78 $329,921 - $522,918	12,516 New	12,516 $523,000

Others Institutions Holding AVIR

# of Institutions

108

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $243M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Atea Pharmaceuticals, Inc. Transaction History